The Coalition for Epidemic Preparedness Innovations (CEPI) and Imperial College London have announced a partnership to develop a self-amplifying RNA vaccine platform (saRNA), enabling tailored vaccine production against multiple viral pathogens.
News
NICE turns down Opdivo/Yervoy combo for kidney cancer
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funds for Opdivo/Yervoy for untreated metastatic renal cell carcinoma.
Winners announced for the Medical & Scientific Excellence Awards!
The winners of the PharmaTimes Medical & Scientific Excellence Awards have been announced – find out who took home the first batch of MSEA pharmas!
Mereo BioPharma and OncoMed propose merger
The UK’s Mereo BioPharma is planning to merge with US group OncoMed Pharmaceuticals.
AZ’ Imfinzi fails in head and neck cancer trial
AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Mallinckrodt to split business
UK-based specialty pharma group Mallinckrodt has unveiled plans to spin-off its specialty generics and active pharmaceutical ingredients business into a new company
NICE OKs NHS funding for Gilead’s CAR T-cell therapy
Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma.
Shire purchase backed by Takeda shareholders
Takeda shareholders have backed the firm’s proposed £46 billion acquisition of Shire.
A third of doctors considering leaving clinical practice
A new report from the General Medical Council (GMC) has found that a third of doctors are considering leaving medical practice, meaning they would no longer be working in clinical facing roles.
UCB to invest £1bn into UK under life sciences sector deal
The government has published the second Life Sciences Sector Deal, detailing both public and private sector investments into the sector, including a £1 billion investment in UK research and development by UCB.
Norgine launches Shield’s Feraccru in the UK
Norgine has launched Feraccru across the UK to treat patients with iron deficiency anaemia, having picked up rights to sell the drug from Shield Therapeutics earlier this year.
First Alzheimer’s drug from Eisai/UCL alliance to enter clinical trials
The first drug candidate from Eisai and University College London (UCL)’s drug discovery collaboration is to enter Phase I clinical trials for Alzheimer’s disease (AD) early next year.
Roche’s Kadcyla cuts risk of breast cancer recurrence after surgery
Roche’s Kadcyla was significantly better than Herceptin at reducing the risk of breast cancer recurrence in certain patients with residual disease after surgery, according to new study findings presented at the San Antonio Breast Cancer Symposium.
Clinical Researcher of the Year – The Americas 2019 is open for entry with a category for everyone!
The PharmaTimes Clinical Researcher of the Year – The Americas in association with MAGI has a broad range of categories to suit all types of clinical researcher.
New Vaccines Centre a ‘major commercial opportunity’
Business Secretary Greg Clark MP has announced the UK’s first dedicated Vaccines Manufacturing Innovation Centre (VMIC), said to represent a “major commercial opportunity”, and also a new front line in the nation’s defence against global pandemic threats.
